NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response. - Wikidata - awgldk - TriplyDB

NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response.

NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response.

http://www.wikidata.org/entity/Q37399422

about

Adaptations of the Secretome of Candida albicans in Response to Host-Related Environmental Conditions Systemic Staphylococcus aureus infection mediated by Candida albicans hyphal invasion of mucosal tissue.Experimental Models of Vaginal Candidiasis and Their Relevance to Human Candidiasis Candida vaginitis: when opportunism knocks, the host responds Applying Convergent Immunity to Innovative Vaccines Targeting Staphylococcus aureus.Fungal vaccines and immunotherapeutics.Mechanisms of NDV-3 vaccine efficacy in MRSA skin versus invasive infection.Exploiting fungal cell wall components in vaccines Vaccines in the treatment of invasive candidiasis.Adaptive immune responses to Candida albicans infection.Identification of Optimal Insertion Site in Recombinant Newcastle Disease Virus (rNDV) Vector Expressing Foreign Gene to Enhance Its Anti-Tumor Effect Proteomic Analysis of Pathogenic Fungi Reveals Highly Expressed Conserved Cell Wall Proteins.Innate immune cell response upon Candida albicans infection Candida antigens and immune responses: implications for a vaccine.The Candida pathogenic species complex.Testing Antifungal Vaccines in an Animal Model of Invasive Candidiasis and in Human Mucosal Candidiasis.IL-17 Receptor Signaling in Oral Epithelial Cells Is Critical for Protection against Oropharyngeal Candidiasis.Glucosamine stimulates pheromone-independent dimorphic transition in Cryptococcus neoformans by promoting Crz1 nuclear translocation.Accessibility and contribution to glucan masking of natural and genetically tagged versions of yeast wall protein 1 of Candida albicans.Patient Susceptibility to Candidiasis-A Potential for Adjunctive Immunotherapy.A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis-A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial.Human Anti-Als3p Antibodies Are Surrogate Markers of NDV-3A Vaccine Efficacy Against Recurrent Vulvovaginal Candidiasis.Candida Immunity

P2860

Q26785119-06A78998-B4BC-4F2E-AA75-EC5600728419 Q27323146-C6EE4A5B-590C-4CC8-B207-72C0D3669D72 Q28077299-B27D3130-ACD9-4872-884F-50A9BFA0126C Q31157510-C0308194-8BAD-446F-A021-EBF1BF988F50 Q34250054-197426C9-158D-4B0D-AB8E-5235F128CB90 Q34400249-A31FA268-2981-4CE1-95C8-B047D5EB3570 Q34792962-7C023E8C-A256-4E2C-9710-3A275591E7F2 Q35085200-FD929419-95E5-4D47-A40A-7E11E99CC2C8 Q36147010-9C50EE4C-F867-4A59-9CC1-C5E8511FC7E6 Q36147114-32748D4A-1A3B-447A-9544-F14AD3A66B8F Q36162804-69928489-2CC2-44A9-AAC5-9C2CAB47EE78 Q36562397-4005AA9E-7DFF-451B-B874-C392F7CFD380 Q37262877-8191BC64-7E40-4561-AFA4-F2368FA1A2AA Q38222636-A76CB15C-8F9E-46E7-886C-9DBDB00A2C23 Q38245727-359BEF66-1854-416B-9130-AE7EB4A02127 Q40183727-CEC9961F-E2F6-4762-8746-432230D0BB07 Q40421383-03CC81EC-0A0A-464F-A40A-0A63A4D67EB8 Q41229705-99984AFA-8D4D-4C99-9B28-42F6690DA3BA Q48252614-EB6350F6-4D24-49FD-A7E9-4CEAAC80C6DF Q49679946-0CAC6C75-E344-4E50-9DA7-F336C1D0FEEC Q52561594-2DC12F26-F137-42FA-91BA-B4643B9910D6 Q55396489-061DC749-624B-48FC-A146-6773CD575EA5 Q59072636-CBF43905-8154-4D87-85B8-17628B9CF8C4

P2860

NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response.

http://www.wikidata.org/entity/Q37399422

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response.

@en

NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response.

@nl

type

label

NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response.

@en

NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response.

@nl

prefLabel

NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response.

@en

NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response.

@nl

P1433

Q37399422-2CDD537B-BE92-4033-A7F3-35986E855A52

P1476

Q37399422-BC287D73-9578-43C5-A86A-C1FF360686C1

P2093

Q37399422-10F355D5-7CD8-4A87-A492-5F9B83FC3436

Q37399422-35CE5EC3-6F39-4D96-B428-F91C6808F026

Q37399422-39B2A4B7-1042-40DB-9434-227D664AF35D

Q37399422-3D0DC359-BEEF-4ACA-9EC4-419A70C00D43

Q37399422-6B8354B7-C45D-4948-A9D0-EE5153F0AB95

Q37399422-831CCA4B-9B2F-42FE-81A2-4F2517474A06

Q37399422-88B45330-C557-4D70-865C-6C9B61229BAD

Q37399422-DE121770-C875-4E6D-B9AB-49ABB3E8B2A3

Q37399422-FE73C383-FD9C-461D-92C7-51896CAE47BB

P2860

Q37399422-00AD9CA9-B9DA-424F-855A-0A551230AA35

Q37399422-01006B3B-F7BA-4D60-9D98-6617BA20B8F3

Q37399422-0D940C34-3998-4136-BF42-8237D5A39EC6

Q37399422-0E15FF8A-F168-4B60-9C4D-7C7D67C6AB87

Q37399422-11259DD9-6266-40CC-87B9-D9B05EB4711F

Q37399422-1BF989A9-CC5E-4881-B39C-2E23C4D4500E

Q37399422-1C14D110-1B4B-4927-B096-6B76F08A7F4C

Q37399422-1E43B5B1-3F56-46B9-BFCB-3BB30A7FDC8D

Q37399422-2245A13B-7B56-4711-9FDC-F99ACA9056A8

Q37399422-251C2E00-D1B8-4C81-99BA-E90C1B9B9709

P304

Q37399422-5BFB2D34-0036-446B-A109-B9C0EB63BC9E

P31

Q37399422-F3D10120-F692-4ACF-8ECC-5011A8FA4B30

P356

Q37399422-A4AED836-2747-4C39-A72E-FD92525D037E

P407

Q37399422-F747CF4F-DE3E-48C2-9AD9-4F96776D9B5C

P433

Q37399422-81391D28-8C9A-4CB4-86EF-091C6714F872

P478

Q37399422-1A743FA7-1760-4817-BCAA-550F2C75CA61

P50

Q37399422-D737A18F-074D-451E-8AC1-1AA4CAF87F68

P577

Q37399422-34A95B2B-5D72-4DE2-83E8-82E7E7E22AD6

P5875

Q37399422-832663D6-6FB5-49A3-B19D-E42C2A46297C

P698

Q37399422-CA1D2513-1887-437B-BE1E-A9F2C5F74929

P932

Q37399422-409DC453-0A63-4C35-AC91-30153ABE72E9

P356

J.VACCINE.2013.09.016

P1433

P1476

NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response.

@en

P2093

Ashraf S Ibrahim

http://www.w3.org/2001/XMLSchema#string

Clint S Schmidt

http://www.w3.org/2001/XMLSchema#string

Guanpingsheng Luo

http://www.w3.org/2001/XMLSchema#string

Hongkyu Lee

http://www.w3.org/2001/XMLSchema#string

John E Edwards

http://www.w3.org/2001/XMLSchema#string

Michael R Yeaman

http://www.w3.org/2001/XMLSchema#string

Samuel W French

http://www.w3.org/2001/XMLSchema#string

Scott G Filler

http://www.w3.org/2001/XMLSchema#string

Teclegiorgis Gebremariam

http://www.w3.org/2001/XMLSchema#string

P2860

Cytokines in the host response to Candida vaginitis: Identifying a role for non-classical immune mediators, S100 alarmins

NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults.

Als3 is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cells.

the hyphal-associated adhesin and invasin Als3 of Candida albicans mediates iron acquisition from host ferritin

Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice.

A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection.

Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity.

Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases.

Host responses to Candida albicans: Th17 cells and mucosal candidiasis.

Functional and structural diversity in the Als protein family of Candida albicans.

P304

5549-5556

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2013.09.016

http://www.w3.org/2001/XMLSchema#string

P407

P433

47

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Hennessey JP Jr

P577

2013-09-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257070828

http://www.w3.org/2001/XMLSchema#string

P698

24063977

http://www.w3.org/2001/XMLSchema#string

P932

3866209

http://www.w3.org/2001/XMLSchema#string